The US FDA has expanded the indication for the Medicines Company's Recothrom for use in children greater than or equal to one month of age.
The recombinant topical thrombin is indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical.
The medication serves as an alternative to bovine or human plasma derived thrombin in patients greater than one month of age.
The Medicines Company senior vice president and chief customer officer Brent Furse said, "We believe the expanded pediatric indication for RECOTHROM provides an opportunity to make this topical hemostat available to a broader range of surgical patients."
